2-{4-[5-({[1-(4-Chloro-phenyl)-methanoyl]-amino}-methyl)-thiophene-2-sulfonyl]-piperazin-1-yl}-8-ethyl-5-oxo-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-{4-[5-({[1-(4-Chloro-phenyl)-methanoyl]-amino}-methyl)-thiophene-2-sulfonyl]-piperazin-1-yl}-8-ethyl-5-oxo-5,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid
• 英文别名: 2-[4-[5-[[(4-Chlorobenzoyl)amino]methyl]thiophen-2-yl]sulfonylpiperazin-1-yl]-8-ethyl-5-oxopyrido[2,3-d]pyrimidine-6-carboxylic acid
• 化学式: C₂₆H₂₅ClN₆O₆S₂
• 分子量: 617.106
• InChiKey: IQKCSXGNUGNTBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  41
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  190
• 氢给体数：
  2
• 氢受体数：
  12

文献信息

• Pharmaceutically active sulfonamide derivatives
  申请人：Applied Research Systems ARS Holding N.V.

  公开号：EP1088821A1

  公开（公告）日：2001-04-04

  The present invention is related to sulfonamide derivatives of formula I notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such sulfonamide derivatives. Said sulfonamide derivatives are efficient modulators of the JNK pathway, they are in particular efficient and selective inhibitors of JNK 2 and 3. The present invention is furthermore related to novel sulfonamide derivatives as well as to methods of their preparation. The compounds of formula I according to the present invention being suitable pharmaceutical agents are those wherein Ar1 and Ar2 are independently from each other substituted or unsubstituted aryl or heteroaryl groups, X is O or S, preferably O; R1 is hydrogen or a C1-C6-alkyl group, preferably H, or R1 forms a substituted or unsubstituted 5-6-membered saturated or non-saturated ring with Ar1; n is an integer from 0 to 5, preferably between 1-3 and most preferred 1. Y within formula I is an unsubstituted or a substituted 4-12-membered saturated cyclic or bicyclic alkyl containing at least one nitrogen atom, whereby one nitrogen atom within said ring is forming a bond with the sulfonyl group of formula I thus providing the sulfonamide.

  本发明涉及公式I的磺酰胺衍生物，特别是用作药物活性化合物，以及含有这种磺酰胺衍生物的制药配方。所述磺酰胺衍生物是JNK途径的高效调节剂，特别是JNK2和3的高效且选择性抑制剂。本发明还涉及新型磺酰胺衍生物以及它们的制备方法。本发明中适合用作药物剂的公式I化合物是Ar1和Ar2分别独立于彼此的取代或未取代芳基或杂环芳基基团，X为O或S，优选为O；R1为氢或C1-C6烷基，优选为H，或R1与Ar1形成取代或未取代的5-6成员饱和或不饱和环；n为0到5的整数，优选为1-3，最优选为1。公式I中的Y是未取代或取代的4-12成员饱和环或双环烷基，其中至少有一个氮原子，该环中的一个氮原子与公式I中的磺酰基形成键合，从而提供磺酰胺。
• PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES
  申请人：Applied Research Systems ARS Holding N.V.

  公开号：EP1218374B1

  公开（公告）日：2005-11-16
• SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES
  申请人：Applied Research Systems ARS Holding N.V.

  公开号：EP1663193A1

  公开（公告）日：2006-06-07
• JNK INHIBITORS FOR TREATMENT OF SKIN DISEASES
  申请人：Laboratoires Serono SA

  公开号：EP2026802A2

  公开（公告）日：2009-02-25
• Sulfonamide derivatives for the treatment of diabetes
  申请人：Rueckle Thomas

  公开号：US20070043027A1

  公开（公告）日：2007-02-22

  The present invention is related to the use of sulfonamide derivatives in the treatment of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type II, inadequate glucose tolerance, insulin resistance, obesity, polycystic ovary syndrome (PCOS). Formula (I). R 1 is selected from the group comprising or consisting of hydrogen, C 1 -C 6 -alkoxy, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, amino, sulfanyl, sulfinyl, sulfonyl, sulfonyloxy, sulfonamide, acylamino, aminocarbonyl, C 1 -C 6 alkoxycarbonyl, aryl, heteroaryl, carboxy, cyano, halogen, hydroxy, nitro, hydrazides. R 2 is selected from the group comprising or consisting of hydrogen, COOR3, —CONR 3 R 3′ , OH, a C 1 -C 4 alkyl substituted with an OH or amino group, a hydrazido carbonyl group, a sulfate, a sulfonate, an amine or an ammonium salt. Y is an 4-12-membered saturated cyclic or bicyclic alkyl containing at least one nitrogen atom, whereby one nitrogen atom within said ring is forming a bond with the sulfonyl group of formula I thus providing the sulfonamide.